首页> 外文期刊>Post?py Higieny i Medycyny Do?wiadczalnej >Endothelial progenitor cells as a new marker of endothelial function with respect to risk of cardiovascular disorders
【24h】

Endothelial progenitor cells as a new marker of endothelial function with respect to risk of cardiovascular disorders

机译:内皮祖细胞是心血管疾病风险中内皮功能的新标志

获取原文
           

摘要

The discovery of endothelial progenitor cells (EPC), over a decade ago, has refuted the previous belief that vasculogenesis only occurs during embryogenesis. The results of several studies revealed altered number and impaired function of EPC in hyperlipidemia, hypertension, diabetes, obesity as well as in rheumatoid arthritis. The population of developmental age is characterized by higher counts of EPC compared to adults. However, among young patients with chronic disorders that affect the vascular system, the number of EPC decreases. The reduced circulating concentration of EPC has become a surrogate marker of endothelial function and has been implicated in the pathogenesis of many vascular diseases. This article aims to review the biology and pathophysiology of EPC in the conditions of cardiovascular risk factors. The potential possibilities of increasing EPC number and function as well as the use of EPC in the treatment of vascular pathology will also be discussed.
机译:十多年前,内皮祖细胞(EPC)的发现驳斥了以前的观点,即血管生成仅在胚胎发生期间发生。几项研究的结果表明,在高脂血症,高血压,糖尿病,肥胖症和类风湿关节炎中,EPC的数量和功能受损。与成年人相比,发育年龄人口的特征在于EPC计数更高。但是,在患有影响血管系统的慢性疾病的年轻患者中,EPC的数量减少了。降低的EPC循环浓度已成为内皮功能的替代标志物,并与许多血管疾病的发病机制有关。本文旨在回顾心血管疾病危险因素条件下EPC的生物学和病理生理学。还将讨论增加EPC数量和功能以及在血管病理学治疗中使用EPC的潜在可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号